Ablynx and Procter & Gamble extend Nanobody drug discovery development agreement to metabolic targets
Advertisement
Ablynx has announced that its drug discovery and development alliance with Procter & Gamble Pharmaceuticals, Inc. (P&GP), a subsidiary of The Procter & Gamble Company, has been extended to include metabolic disease targets. Through this agreement, Ablynx will use its unique and patent protected Nanobody(TM) platform to discover and develop drug candidates against targets specified by P&GP.
Under terms of the agreement, P&GP provides Ablynx with research and development funding, milestone payments, and royalties upon commercialization. Ablynx is responsible for discovering Nanobodies(TM) that meet an agreed product profile. P&GP assumes responsibility for the pre-clinical and clinical development of lead Nanobodies(TM), as well as the commercialization of any resulting drug products. The financial terms of the agreement are not disclosed.
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Antisense Pharma Granted Patents on Medical Device for Application of Neurotherapeutics
Molecular Profiles Invests £9 million in New Facility To Increase Manufacturing Capabilities for Phase I and II Clinical Trials
EyeTechCare raises EUR 7.5 million in a second funding round and speeds up its development
David Evans steps down as chairman of the board for Horizon Discovery
New clinical and preclinical data on Basilea's novel antibiotic BAL30072 against multidrug-resistant Gram-negative superbugs
Parkinson’s researchers test a new approach against motor disorders
New virus drug will have to shoot at moving targets
New research may lead to improved diagnosis of autism
BioGaia initiates investigative study in type 2 diabetics
Viruses flourish in guts of healthy babies
Amorfix Life Sciences and Biogen Idec to collaborate on research for ALS disease